diroximel fumarate (DRF)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, King's College London

Conditions

Relapsing Multiple SclerosisSchizophrenia Disorders

Unknown Phase

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

RecruitingNCT05344469

Novartis PharmaceuticalsRelapsing Multiple Sclerosis

Start: 2022-05-10End: 2029-05-30Target: 800Updated: 2026-07-30

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

RecruitingNCT06957808

King's College LondonSchizophrenia Disorders

Start: 2025-01-10End: 2027-01-20Target: 30Updated: 2026-02-13